한글목차

세계 진단용 방사성동위원소 시장의 미래는 병원, 전문 클리닉, 진단 센터, 학술 및 연구 기관 시장의 기회로 인해 유망합니다. 세계 진단용 방사성동위원소 시장은 2025년부터 2031년까지 6.7%의 CAGR로 2031년까지 약 69억 달러에 달할 것으로 예상됩니다. 이 시장의 주요 촉진요인은 질병의 조기 및 정확한 진단에 대한 수요 증가, 진단용 영상 양식의 발전, 알파 방사성동위원소에 대한 수요 증가입니다.

• Lucintel의 예측에 따르면, 방사성동위원소별로는 테크네튬-99m 부문이 예측 기간 동안 가장 높은 성장세를 보일 것으로 예상됩니다.
• 최종사용자 카테고리에서는 전문 클리닉이 예측 기간 동안 가장 높은 성장을 보일 것으로 예상됩니다.
• 지역별로는 북미가 예측 기간 동안 가장 큰 지역으로 남을 것으로 예상됩니다.

진단용 방사성동위원소 시장의 전략적 성장 기회

진단용 방사성동위원소 시장은 기술, 생산 및 진단 기술의 발전으로 인해 주요 응용 분야에서 몇 가지 전략적 성장 기회를 제공하고 있습니다.

• 종양학에서의 PET 영상 확대 : 암 진단에서 PET 영상 활용 확대는 큰 성장 기회로, PET 방사성동위원소에 대한 접근성이 확대됨에 따라 암의 조기 발견과 치료 계획을 개선할 수 있게 됩니다.
• 하이브리드 이미징 기술 개발 : PET-CT와 PET-MRI의 하이브리드 기술에 대한 투자는 보다 정밀한 진단 도구를 제공함으로써 성장 기회를 제공합니다. 이러한 시스템을 통해 의료진은 암이나 심혈관질환과 같은 복잡한 질환의 진단 정확도를 향상시킬 수 있습니다.
• 비우라늄 동위원소 생산 증가 : 비우라늄 기반 진단용 동위원소 생산은 성장 잠재력이 있습니다. 이러한 기술 개발은 환경적 우려를 줄이고 보다 지속가능하고 안정적인 동위원소 공급을 실현할 수 있습니다.
• 신흥 시장 진출 : 신흥 시장, 특히 아시아와 라틴아메리카에서 확대되는 의료 인프라는 진단용 방사성동위원소의 생산과 접근성을 확대할 수 있는 기회를 제공합니다. 이러한 확장은 의료 불평등을 해소하고, 의료 서비스가 부족한 지역의 진단 능력을 향상시킬 수 있습니다.
• 저선량 이미징 기술에 대한 투자 : 방사선 피폭을 줄이는 방사성동위원소 이미징 기술 개발은 성장의 기회가 될 것입니다. 이러한 기술 혁신은 영상 진단을 더욱 안전하게 만들고, 조기 진단과 빈번한 진단에 폭넓게 적용될 수 있도록 돕습니다.

이러한 전략적 성장 기회는 진단용 방사성동위원소 분야의 기술 혁신과 시장 확대 잠재력을 강조하며, PET 이미징, 하이브리드 시스템, 비우라늄 동위원소 생산, 신흥 시장, 저선량 기술에 집중함으로써 기업들은 성장을 촉진하고 환자 치료 결과를 개선할 수 있습니다.

진단용 방사성동위원소 시장의 촉진요인 및 과제

진단용 방사성동위원소 시장은 성장과 개척을 형성하는 다양한 촉진요인 및 과제에 영향을 받습니다. 이러한 요인을 이해하는 것은 시장을 효과적으로 탐색하는 데 필수적입니다.

진단용 방사성동위원소 시장을 이끄는 요인은 다음과 같습니다:

• 질병 조기발견에 대한 수요 증가 : 암, 심혈관질환 등 질병의 조기발견이 중요해지면서 진단용 방사성동위원소, 특히 PET 및 SPECT 동위원소에 대한 수요가 증가하고 있습니다.
• 이미징 기술의 발전 : 하이브리드 시스템 및 AI 통합과 같은 이미징 기술 혁신은 진단 정확도를 향상시키고 방사성동위원소 기반 진단의 추가 채택을 촉진하고 있습니다.
• 세계 고령화 : 세계 인구의 고령화에 따라 만성질환의 유병률이 증가함에 따라 조기 발견 및 모니터링을 위해 방사성동위원소에 의존하는 영상 진단에 대한 수요가 증가하고 있습니다.
• 정부 지원 증가 : 특히 의료 자급자족을 목표로 하는 국가에서는 진단용 동위원소의 안정적인 공급을 확보하기 위해 세계 각국 정부가 핵의학 연구와 방사성동위원소 생산에 투자하고 있습니다.
• 비우라늄 생산 이용 확대 : 비우라늄 기반 동위원소 생산으로의 전환은 환경 문제에 대한 우려와 테크네튬-99m과 같은 주요 동위원소의 안정적 공급망 확보에 대한 기대에 힘입어 더욱 탄력을 받고 있습니다.

진단용 방사성동위원소 시장의 과제는 다음과 같습니다:

• 높은 방사성동위원소 제조 비용 : 특히 사이클로트론 제조와 같은 고도의 방법을 통한 진단용 방사성동위원소 제조 비용은 엄청나기 때문에 특정 지역에서의 접근이 제한되어 시장 확대에 영향을 미칠 수 있습니다.
• 공급망 혼란 : 진단용 동위원소의 세계 공급망은 취약할 수 있으며, 생산 중단은 테크네튬-99m과 같은 주요 동위원소의 가용성에 영향을 미쳐 진단 절차의 지연을 초래할 수 있습니다.
• 규제 장애물 : 방사성동위원소의 제조, 취급 및 폐기에 대한 엄격한 규제 요건은 특히 원자력 규제가 복잡한 지역에서는 시장 성장을 둔화시킬 수 있습니다.

진단용 방사성동위원소 시장은 기술 발전, 질병 조기 발견에 대한 수요 증가, 정부 지원 증가에 힘입어 성장하고 있습니다. 그러나 제조 비용 상승, 공급망 혼란, 규제 장애물, 신흥 시장에서의 접근성 제한과 같은 도전과제를 해결해야 합니다. 이러한 시장 촉진요인과 도전과제의 균형을 맞추는 것이 시장 성장의 지속적 성장의 열쇠가 될 것입니다.

목차

제1장 주요 요약

제2장 세계의 진단용 방사성동위원소 시장 : 시장 역학

• 소개, 배경, 분류
• 공급망
• 업계 성장 촉진요인과 과제

제3장 시장 동향과 예측 분석(2019-2031년)

• 거시경제 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 진단용 방사성동위원소 시장 동향(2019-2024년)과 예측(2025-2031년)
• 세계의 진단용 방사성동위원소 시장 : 방사성동위원소별
  • 테크네튬 99m　
  • 탈륨 201　
  • 갈륨 67　
  • 요오드 123　
  • FDG
  • 루비듐 82　
  • 기타
• 세계의 진단용 방사성동위원소 시장 : 영상 모달리티별
  • SPECT
  • PET
  • β방사체
• 세계의 진단용 방사성동위원소 시장 : 용도별
  • 진단용
  • 치료용
• 세계의 진단용 방사성동위원소 시장 : 최종 용도별
  • 병원
  • 전문 클리닉
  • 진단 센터
  • 학술연구기관
  • 기타

제4장 지역별 시장 동향과 예측 분석(2019-2031년)

• 세계의 진단용 방사성동위원소 시장 : 지역별
• 북미의 진단용 방사성동위원소 시장
• 유럽의 진단용 방사성동위원소 시장
• 아시아태평양의 진단용 방사성동위원소 시장
• 기타 지역의 진단용 방사성동위원소 시장

제5장 경쟁 분석

• 제품 포트폴리오 분석
• 운영 통합
• Porter's Five Forces 분석

제6장 성장 기회와 전략 분석

• 성장 기회 분석
  • 세계의 진단용 방사성동위원소 시장 성장 기회 : 방사성동위원소별
  • 세계의 진단용 방사성동위원소 시장 성장 기회 : 영상 모달리티별
  • 세계의 진단용 방사성동위원소 시장 성장 기회 : 용도별
  • 세계의 진단용 방사성동위원소 시장 성장 기회 : 최종 용도별
  • 세계의 진단용 방사성동위원소 시장 성장 기회 : 지역별
• 세계의 진단용 방사성동위원소 시장 최신 동향
• 전략적 분석
  • 신제품 개발
  • 세계의 진단용 방사성동위원소 시장 생산능력 확대
  • 세계의 진단용 방사성동위원소 시장 기업 인수합병(M&A), 합작투자
  • 인증과 라이선싱

제7장 주요 기업 개요

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Cardinal Health
• Lantheus Holdings
• Bayer
• Bracco
• Eckert & Ziegler

영문목차

The future of the global diagnostic radioisotope market looks promising with opportunities in the hospital, specialty clinic, diagnostic center, and academic & research institute markets. The global diagnostic radioisotope market is expected to reach an estimated $6.9 billion by 2031 with a CAGR of 6.7% from 2025 to 2031. The major drivers for this market are the increasing demand for early and accurate diagnosis of diseases, growing advancements in diagnostics imaging modalities, and expanding demand for alpha radioisotopes.

• Lucintel forecasts that, within the radioisotope category, the technetium-99m segment is expected to witness the highest growth over the forecast period.
• Within the end use category, specialty clinic is expected to witness the highest growth over the forecast period.
• In terms of regions, North America will remain the largest region over the forecast period.

Gain valuable insights for your business decisions with our comprehensive 150+ page report.

Emerging Trends in the Diagnostic Radioisotope Market

The diagnostic radioisotope market is evolving, driven by advancements in technology, improved production methods, and increased demand for precise diagnostic tools in healthcare.

• Growing Demand for PET Imaging: The use of PET imaging is expanding due to its effectiveness in detecting cancer and neurological disorders. This trend is increasing the demand for PET radioisotopes like FDG, which are essential for accurate diagnosis.
• Non-Uranium-Based Production: There is a growing shift toward non-uranium-based methods for producing diagnostic radioisotopes. These methods are safer and more sustainable, reducing environmental concerns while ensuring a reliable supply for medical use.
• Hybrid Imaging Systems: The integration of PET with CT or MRI is becoming more common, offering improved diagnostic accuracy. This trend is reshaping diagnostic practices, particularly in cancer, cardiovascular, and neurological imaging.
• Focus on Reducing Radiation Exposure: New advancements aim to reduce the radiation dose patients receive during diagnostic procedures. This trend improves patient safety, making radioisotope-based imaging a more appealing option for frequent and early-stage diagnostics.
• Increased Self-Sufficiency in Production: Countries are focusing on becoming self-sufficient in radioisotope production to avoid supply chain disruptions. This trend is driving investments in local facilities and technologies to produce essential diagnostic isotopes domestically.

These trends are reshaping the diagnostic radioisotope market by enhancing diagnostic capabilities, improving safety, and addressing global supply chain concerns. The growing use of PET imaging, hybrid systems, and sustainable production methods is driving innovation and expanding the market's reach.

Recent Developments in the Diagnostic Radioisotope Market

Key developments in the diagnostic radioisotope market reflect technological advancements and strategic investments aimed at improving isotope availability and diagnostic accuracy.

• Non-Uranium Production Methods: The adoption of non-uranium-based production for Technetium-99m is reducing reliance on uranium, ensuring a more sustainable supply chain, and improving global access to this critical diagnostic isotope.
• Expansion of PET Isotope Production: Countries like China and India are increasing PET isotope production, particularly FDG, which is essential for cancer diagnostics. These developments are helping to meet the rising demand for PET imaging in oncology.
• Development of Hybrid Imaging Systems: The introduction of hybrid PET-CT and PET-MRI systems in countries like Germany is enhancing diagnostic precision, particularly in complex cases such as cancer metastasis, cardiovascular disease, and neurological disorders.
• Collaborative Research and Production: In India, collaborations between hospitals and research institutions are improving access to diagnostic radioisotopes, particularly in underserved regions. These partnerships aim to address healthcare inequalities and enhance diagnostic services.
• Reduction in Radiation Dose: Japan is at the forefront of reducing radiation exposure in radioisotope imaging, focusing on innovations that maintain image quality while minimizing the risks associated with radiation.

These developments are advancing the diagnostic radioisotope market by improving production methods, enhancing diagnostic precision, and making radioisotope imaging safer and more accessible. The focus on sustainability, technological innovation, and collaboration is driving growth in the market.

Strategic Growth Opportunities for Diagnostic Radioisotope Market

The diagnostic radioisotope market offers several strategic growth opportunities across key applications, driven by advancements in technology, production, and diagnostic techniques.

• Expansion of PET Imaging in Oncology: The increasing use of PET imaging for cancer diagnostics presents a major growth opportunity. Expanding access to PET radioisotopes can improve early cancer detection and treatment planning.
• Development of Hybrid Imaging Technologies: Investing in hybrid PET-CT and PET-MRI technologies offers growth opportunities by providing more precise diagnostic tools. These systems enable healthcare providers to improve accuracy in diagnosing complex conditions like cancer and cardiovascular disease.
• Increased Production of Non-Uranium Isotopes: There is potential for growth in the production of non-uranium-based diagnostic isotopes. Developing these technologies can reduce environmental concerns and provide a more sustainable and reliable isotope supply.
• Expansion into Emerging Markets: Growing healthcare infrastructure in emerging markets, particularly in Asia and Latin America, presents opportunities for expanding diagnostic radioisotope production and access. This expansion can address healthcare inequalities and improve diagnostic capabilities in underserved areas.
• Investment in Low-Dose Imaging Technologies: Developing radioisotope imaging technologies that reduce radiation exposure presents a growth opportunity. These innovations can make diagnostic imaging safer, encouraging broader adoption for early and frequent diagnostics.

These strategic growth opportunities highlight the potential for innovation and market expansion in the diagnostic radioisotope sector. By focusing on PET imaging, hybrid systems, non-uranium isotope production, emerging markets, and low-dose technologies, companies can drive growth and improve patient outcomes.

Diagnostic Radioisotope Market Driver and Challenges

The diagnostic radioisotope market is influenced by various drivers and challenges that shape its growth and development. Understanding these factors is essential for navigating the market effectively.

The factors responsible for driving the diagnostic radioisotope market include:

• Rising Demand for Early Disease Detection: The growing emphasis on early detection of diseases like cancer and cardiovascular conditions is driving demand for diagnostic radioisotopes, particularly PET and SPECT isotopes.
• Technological Advancements in Imaging: Innovations in imaging technologies, such as hybrid systems and AI integration, are improving diagnostic accuracy, driving further adoption of radioisotope-based diagnostics.
• Global Aging Population: As the global population ages, the prevalence of chronic diseases increases, fueling the demand for diagnostic imaging procedures that rely on radioisotopes for early detection and monitoring.
• Increased Government Support: Governments worldwide are investing in nuclear medicine research and radioisotope production to ensure a stable supply of diagnostic isotopes, particularly in countries aiming for healthcare self-sufficiency.
• Growing Use of Non-Uranium Production: The shift toward non-uranium-based isotope production is gaining momentum, driven by environmental concerns and the desire to secure a stable supply chain for key isotopes like Technetium-99m.

Challenges in the diagnostic radioisotope market are:

• High Cost of Radioisotope Production: The cost of producing diagnostic radioisotopes, particularly through advanced methods like cyclotron production, can be prohibitive, limiting access in certain regions and affecting market expansion.
• Supply Chain Disruptions: The global supply chain for diagnostic isotopes can be fragile, with production disruptions affecting the availability of key isotopes like Technetium-99m, leading to delays in diagnostic procedures.
• Regulatory Hurdles: Strict regulatory requirements for the production, handling, and disposal of radioisotopes can slow down market growth, particularly in regions with complex nuclear regulations.

The diagnostic radioisotope market is driven by technological advancements, rising demand for early disease detection, and increasing government support. However, challenges such as high production costs, supply chain disruptions, regulatory hurdles, and limited access in emerging markets must be addressed. Balancing these drivers and challenges is key to sustaining growth in the market.

List of Diagnostic Radioisotope Companies

Companies in the market compete on the basis of product quality offered. Major players in this market focus on expanding their manufacturing facilities, R&D investments, infrastructural development, and leverage integration opportunities across the value chain. Through these strategies diagnostic radioisotope companies cater increasing demand, ensure competitive effectiveness, develop innovative products & technologies, reduce production costs, and expand their customer base. Some of the diagnostic radioisotope companies profiled in this report include-

• GE Healthcare
• Siemens Healthineers
• Koninklijke Philips
• Cardinal Health
• Lantheus Holdings
• Bayer
• Bracco
• Eckert & Ziegler
• Nordion
• NTP Radioisotopes

Diagnostic Radioisotope by Segment

The study includes a forecast for the global diagnostic radioisotope market by radioisotope, imaging modality, application, end use, and region.

Diagnostic Radioisotope Market by Radioisotope [Analysis by Value from 2019 to 2031]:

• Technetium-99m
• Thallium-201
• Gallium-67
• Iodine-123
• FDG
• Rubidium-82
• Others

Diagnostic Radioisotope Market by Imaging Modality [Analysis by Value from 2019 to 2031]:

• SPECT
• PET
• Beta Emitters

Diagnostic Radioisotope Market by Application [Analysis by Value from 2019 to 2031]:

• Diagnostic
• Therapeutic

Diagnostic Radioisotope Market by End Use [Analysis by Value from 2019 to 2031]:

• Hospitals
• Specialty Clinics
• Diagnostic Centers
• Academic & Research Institutes
• Others

Diagnostic Radioisotope Market by Region [Analysis by Value from 2019 to 2031]:

• North America
• Europe
• Asia Pacific
• The Rest of the World

Country Wise Outlook for the Diagnostic Radioisotope Market

Major players in the market are expanding their operations and forming strategic partnerships to strengthen their positions. Below image highlights recent developments by major diagnostic radioisotope producers in key regions: the USA, China, India, Japan, and Germany

• United States: The U.S. is advancing the production of Technetium-99m, the most widely used radioisotope in diagnostics. Recent developments include the establishment of non-uranium-based production facilities, which enhance the supply chain and reduce dependence on imported isotopes, ensuring a stable supply for medical imaging.
• China: China is increasing its capacity for radioisotope production, focusing on expanding the use of PET (Positron Emission Tomography) imaging. Recent developments include new cyclotrons to produce fluorodeoxyglucose (FDG) for PET scans, aimed at improving cancer diagnostics and broader healthcare access.
• Germany: In Germany, advancements in diagnostic radioisotope technologies focus on the development of hybrid imaging systems that combine PET with CT or MRI. These innovations improve diagnostic accuracy, particularly in oncology, cardiology, and neurology, enhancing patient outcomes through more precise imaging.
• India: India has made significant strides in self-sufficiency for radioisotope production, with the government investing in new research reactors. Recent developments include collaborations between hospitals and research institutions to increase the availability of radioisotopes for diagnostic purposes, particularly in rural and underserved areas.
• Japan: Japan is leveraging technological innovations to enhance the production and use of diagnostic radioisotopes. Recent developments focus on reducing radiation doses in medical imaging, improving patient safety while maintaining high imaging quality, especially in cancer detection and cardiovascular diagnostics.

Features of the Global Diagnostic Radioisotope Market

Market Size Estimates: Diagnostic radioisotope market size estimation in terms of value ($B).

Trend and Forecast Analysis: Market trends (2019 to 2024) and forecast (2025 to 2031) by various segments and regions.

Segmentation Analysis: Diagnostic radioisotope market size by various segments, such as by radioisotope, imaging modality, application, end use, and region in terms of value ($B).

Regional Analysis: Diagnostic radioisotope market breakdown by North America, Europe, Asia Pacific, and Rest of the World.

Growth Opportunities: Analysis of growth opportunities in different radioisotopes, imaging modalities, applications, end uses, and regions for the diagnostic radioisotope market.

Strategic Analysis: This includes M&A, new product development, and competitive landscape of the diagnostic radioisotope market.

Analysis of competitive intensity of the industry based on Porter's Five Forces model.

If you are looking to expand your business in this market or adjacent markets, then contact us. We have done hundreds of strategic consulting projects in market entry, opportunity screening, due diligence, supply chain analysis, M & A, and more.

This report answers following 11 key questions:

• Q.1. What are some of the most promising, high-growth opportunities for the diagnostic radioisotope market by radioisotope (technetium-99m, thallium-201, gallium-67, iodine-123, FDG, rubidium-82, and others), imaging modality (SPECT, PET, and beta emitters), application (diagnostic and therapeutic), end use (hospitals, specialty clinics, diagnostic centers, academic & research institutes, and others), and region (North America, Europe, Asia Pacific, and the Rest of the World)?
• Q.2. Which segments will grow at a faster pace and why?
• Q.3. Which region will grow at a faster pace and why?
• Q.4. What are the key factors affecting market dynamics? What are the key challenges and business risks in this market?
• Q.5. What are the business risks and competitive threats in this market?
• Q.6. What are the emerging trends in this market and the reasons behind them?
• Q.7. What are some of the changing demands of customers in the market?
• Q.8. What are the new developments in the market? Which companies are leading these developments?
• Q.9. Who are the major players in this market? What strategic initiatives are key players pursuing for business growth?
• Q.10. What are some of the competing products in this market and how big of a threat do they pose for loss of market share by material or product substitution?
• Q.11. What M&A activity has occurred in the last 5 years and what has its impact been on the industry?

Table of Contents

1. Executive Summary

2. Global Diagnostic Radioisotope Market : Market Dynamics

• 2.1: Introduction, Background, and Classifications
• 2.2: Supply Chain
• 2.3: Industry Drivers and Challenges

3. Market Trends and Forecast Analysis from 2019 to 2031

• 3.1. Macroeconomic Trends (2019-2024) and Forecast (2025-2031)
• 3.2. Global Diagnostic Radioisotope Market Trends (2019-2024) and Forecast (2025-2031)
• 3.3: Global Diagnostic Radioisotope Market by Radioisotope
  • 3.3.1: Technetium-99m
  • 3.3.2: Thallium-201
  • 3.3.3: Gallium-67
  • 3.3.4: Iodine-123
  • 3.3.5: FDG
  • 3.3.6: Rubidium-82
  • 3.3.7: Others
• 3.4: Global Diagnostic Radioisotope Market by Imaging Modality
  • 3.4.1: SPECT
  • 3.4.2: PET
  • 3.4.3: Beta Emitters
• 3.5: Global Diagnostic Radioisotope Market by Application
  • 3.5.1: Diagnostic
  • 3.5.2: Therapeutic
• 3.6: Global Diagnostic Radioisotope Market by End Use
  • 3.6.1: Hospitals
  • 3.6.2: Specialty Clinics
  • 3.6.3: Diagnostic Centers
  • 3.6.4: Academic & Research Institutes
  • 3.6.5: Others

4. Market Trends and Forecast Analysis by Region from 2019 to 2031

• 4.1: Global Diagnostic Radioisotope Market by Region
• 4.2: North American Diagnostic Radioisotope Market
  • 4.2.1: North American Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.2.2: North American Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.3: European Diagnostic Radioisotope Market
  • 4.3.1: European Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.3.2: European Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.4: APAC Diagnostic Radioisotope Market
  • 4.4.1: APAC Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.4.2: APAC Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others
• 4.5: ROW Diagnostic Radioisotope Market
  • 4.5.1: ROW Diagnostic Radioisotope Market by Radioisotope: Technetium-99m, Thallium-201, Gallium-67, Iodine-123, FDG, Rubidium-82, and Others
  • 4.5.2: ROW Diagnostic Radioisotope Market by End Use: Hospitals, Specialty Clinics, Diagnostic Centers, Academic & Research Institutes, and Others

5. Competitor Analysis

• 5.1: Product Portfolio Analysis
• 5.2: Operational Integration
• 5.3: Porter's Five Forces Analysis

6. Growth Opportunities and Strategic Analysis

• 6.1: Growth Opportunity Analysis
  • 6.1.1: Growth Opportunities for the Global Diagnostic Radioisotope Market by Radioisotope
  • 6.1.2: Growth Opportunities for the Global Diagnostic Radioisotope Market by Imaging Modality
  • 6.1.3: Growth Opportunities for the Global Diagnostic Radioisotope Market by Application
  • 6.1.4: Growth Opportunities for the Global Diagnostic Radioisotope Market by End Use
  • 6.1.5: Growth Opportunities for the Global Diagnostic Radioisotope Market by Region
• 6.2: Emerging Trends in the Global Diagnostic Radioisotope Market
• 6.3: Strategic Analysis
  • 6.3.1: New Product Development
  • 6.3.2: Capacity Expansion of the Global Diagnostic Radioisotope Market
  • 6.3.3: Mergers, Acquisitions, and Joint Ventures in the Global Diagnostic Radioisotope Market
  • 6.3.4: Certification and Licensing

7. Company Profiles of Leading Players

• 7.1: GE Healthcare
• 7.2: Siemens Healthineers
• 7.3: Koninklijke Philips
• 7.4: Cardinal Health
• 7.5: Lantheus Holdings
• 7.6: Bayer
• 7.7: Bracco
• 7.8: Eckert & Ziegler